Third, carotenoids and their retinoid conversion products are potential therapeutic targets for AD treatment because of their capability to affect plaque formation, cholinergic transmission, ApoE and ABCA1 expressions, cholesterol content in the gut microbiota, and the pro-inflammatory environment of the brain [113]. This evidence concerns the gene ABCA1 and Alzheimer disease.